Innovations and emerging trends in adoptive cell therapies for solid tumors: engineering strategies and clinical translation
- 1Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University
Abstract
Cancer remains a formidable challenge in global oncology, with conventional treatments often failing to achieve durable responses in advanced stages. Adoptive cell therapy (ACT), despite its revolutionary success in hematological malignancies, faces critical bottlenecks in solid tumors, including a hostile immunosuppressive tumor microenvironment (TME), restricted cellular trafficking, and the rapid onset of T-cell exhaustion. This review systematically explores the evolution of ACT platforms, ranging from foundational tumor-infiltrating lymphocytes (TILs) to precision-engineered chimeric antigen receptor (CAR)-T and T-cell receptor (TCR)-T therapies. We highlight how innovative engineering strategies such as the integration of “armored” CARs, synthetic gene circuits, and CRISPR/Cas9-mediated gene editing have been employed to enhance the persistence and polyfunctionality of effector cells. Beyond T-cell-centric approaches, we examine the emerging landscape of diverse immune effector cells, including CAR-natural killer (NK) cells, and CAR-macrophages (CAR-M), which offer unique advantages in antigen recognition and safety profiles. Furthermore, we detail the synergistic potential of multimodal combination regimens, where ACT is paired with immune checkpoint inhibitors (ICIs), localized radiotherapy, or nanotechnology-based delivery systems to dismantle TME barriers and achieve systemic anti-tumor immunity. By tracing the journey of therapeutic cells from ex vivo expansion to intratumoral infiltration and cytotoxicity, this review illuminates the molecular mechanisms governing therapeutic efficacy. Finally, we discuss the current clinical trial landscape, manufacturing hurdles, and the regulatory pathways essential for transitioning these sophisticated cellular products from bench to bedside. Graphical abstract
Related
- Editorial: Translational strategies for chronic lung diseases: emerging therapies and precision medicine
- Systemic Therapies in Advanced Adrenocortical Carcinoma: Current Standards, Emerging Strategies, and Practical Considerations
- The Evolving Landscape of Hypertrophic Cardiomyopathy: Clinical Assessment, Precision Therapies, and Emerging Strategies
- Emerging mechanism-driven therapies for endometriosis: From GnRH antagonists to microbiome and device-based strategies (Review).
- Engineering CAR-T cell therapies for digestive tract cancer: advances, challenges, and strategies to overcome tumor heterogeneity and immunosuppressive barriers.
BibTeX
@article{huang2026innovations,
title = {{Innovations and emerging trends in adoptive cell therapies for solid tumors: engineering strategies and clinical translation}},
author = {Peng Huang and WenLin Wu and Yu Min and Yi Zhang and YunFeng Tao and Zheran Liu and Zhigong Wei and Xingchen Peng},
journal = {Experimental Hematology \& Oncology},
year = {2026},
month = oct,
doi = {10.1186/s40164-026-00848-3},
url = {https://doi.org/10.1186/s40164-026-00848-3},
note = {CC BY},
}
RIS
TY - JOUR
TI - Innovations and emerging trends in adoptive cell therapies for solid tumors: engineering strategies and clinical translation
AU - Peng Huang
AU - WenLin Wu
AU - Yu Min
AU - Yi Zhang
AU - YunFeng Tao
AU - Zheran Liu
AU - Zhigong Wei
AU - Xingchen Peng
PY - 2026
DA - 2026/10/25
JO - Experimental Hematology & Oncology
DO - 10.1186/s40164-026-00848-3
UR - https://doi.org/10.1186/s40164-026-00848-3
AB - Cancer remains a formidable challenge in global oncology, with conventional treatments often failing to achieve durable responses in advanced stages. Adoptive cell therapy (ACT), despite its revolutionary success in hematological malignancies, faces critical bottlenecks in solid tumors, including a hostile immunosuppressive tumor microenvironment (TME), restricted cellular trafficking, and the rapid onset of T-cell exhaustion. This review systematically explores the evolution of ACT platforms, ranging from foundational tumor-infiltrating lymphocytes (TILs) to precision-engineered chimeric antigen receptor (CAR)-T and T-cell receptor (TCR)-T therapies. We highlight how innovative engineering strategies such as the integration of “armored” CARs, synthetic gene circuits, and CRISPR/Cas9-mediated gene editing have been employed to enhance the persistence and polyfunctionality of effector cells. Beyond T-cell-centric approaches, we examine the emerging landscape of diverse immune effector cells, including CAR-natural killer (NK) cells, and CAR-macrophages (CAR-M), which offer unique advantages in antigen recognition and safety profiles. Furthermore, we detail the synergistic potential of multimodal combination regimens, where ACT is paired with immune checkpoint inhibitors (ICIs), localized radiotherapy, or nanotechnology-based delivery systems to dismantle TME barriers and achieve systemic anti-tumor immunity. By tracing the journey of therapeutic cells from ex vivo expansion to intratumoral infiltration and cytotoxicity, this review illuminates the molecular mechanisms governing therapeutic efficacy. Finally, we discuss the current clinical trial landscape, manufacturing hurdles, and the regulatory pathways essential for transitioning these sophisticated cellular products from bench to bedside. Graphical abstract
SN - 2162-3619
ER -